NEEDHAM, MASS., Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) — Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a corporate update summarizing previously disclosed program developments and reinforcing the Company’s strategic direction entering 2026. (BioXyTran)Corporate Update Highlights (Previously Disclosed)ProLectin‑M (broad-spectrum antiviral platform)Bioxytran’s lead antiviral program, ProLectin‑M, is being developed under an active U.S. FDA Investigational New Drug (IND) framework, as previously announced by the Company. In October 2025, the Company announced the completion of a randomized, double-blind, placebo-controlled clinical trial for ProLectin‑M and stated that data from the trial is expected to help inform Phase 3 trial design and be submitted to regulators pursuant to prior regulatory interactions. (BioXyTran)In May 2025, Bioxytran also announced completion of dose optimization work intended to support additional clinical trial planning an...